719 related articles for article (PubMed ID: 33619261)
21. FLT3 inhibitors in AML: are we there yet?
Sudhindra A; Smith CC
Curr Hematol Malig Rep; 2014 Jun; 9(2):174-85. PubMed ID: 24682858
[TBL] [Abstract][Full Text] [Related]
22. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
23. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
[TBL] [Abstract][Full Text] [Related]
24. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
[TBL] [Abstract][Full Text] [Related]
25. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
26. [Novel therapies in AML and their resistance mechanisms].
Takahashi K
Rinsho Ketsueki; 2022; 63(9):1052-1057. PubMed ID: 36198529
[TBL] [Abstract][Full Text] [Related]
27. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
McMahon CM; Perl AE
Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutics in acute myeloid leukemia.
Sweet K; Lancet JE
Curr Hematol Malig Rep; 2014 Jun; 9(2):109-17. PubMed ID: 24633743
[TBL] [Abstract][Full Text] [Related]
29. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
Yilmaz M; Daver N
Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
[TBL] [Abstract][Full Text] [Related]
30. A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
Bazinet A; Assouline S
Expert Rev Hematol; 2021 Feb; 14(2):185-197. PubMed ID: 33430671
[No Abstract] [Full Text] [Related]
31. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
Gorcea CM; Burthem J; Tholouli E
Future Oncol; 2018 Aug; 14(20):1995-2004. PubMed ID: 29498296
[TBL] [Abstract][Full Text] [Related]
32. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
33. New Treatment Options for Acute Myeloid Leukemia in 2019.
Cerrano M; Itzykson R
Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
[TBL] [Abstract][Full Text] [Related]
34. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract][Full Text] [Related]
35. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
36. Is targeted therapy feasible in acute myelogenous leukemia?
Konig H; Levis M
Curr Hematol Malig Rep; 2014 Jun; 9(2):118-27. PubMed ID: 24599573
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Giri S; Hamdeh S; Bhatt VR; Schwarz JK
J Natl Compr Canc Netw; 2015 May; 13(5):508-14. PubMed ID: 25964636
[TBL] [Abstract][Full Text] [Related]
38. Novel Therapies in Acute Myeloid Leukemia.
Mukherjee S; Sekeres MA
Semin Oncol Nurs; 2019 Dec; 35(6):150955. PubMed ID: 31759818
[TBL] [Abstract][Full Text] [Related]
39. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger M; Lengerke C; Passweg J
Cancer Genomics Proteomics; 2016 09-10; 13(5):317-29. PubMed ID: 27566651
[TBL] [Abstract][Full Text] [Related]
40. [Molecular targeted therapy for acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2023; 64(5):345-354. PubMed ID: 37271525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]